NEJM study points to new era in hepatitis C treatment

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news163418460.html">NEJM study points to new era in hepatitis C treatment</a></p> <p>For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.</p>